Odyssey Health, Inc.
For the period ended Apr 30, 2026. Filed Jun 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 30, 2026 · Filed Jun 12, 2026
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Dollars | Capital | Deficit | Deficit | |
| Balances, July 31, 2025 | 96,709,763 | $96,710 | $55,694,429 | $(62,745,837) | $(6,954,698) |
| Common stock issued for conversion of accrued interest and fees | 1,144,000 | 1,144 | 81,224 | – | 82,368 |
| Common stock issued for conversion of outstanding principal | 2,000,000 | 2,000 | 142,000 | – | 144,000 |
| Warrants issued in debt financing | – | – | 56,589 | – | 56,589 |
| Net loss | – | – | – | (483,447) | (483,447) |
| Balances, October 31, 2025 | 99,853,763 | 99,854 | 55,974,242 | (63,229,284) | (7,155,188) |
| Warrants issued in debt financing | – | – | 160,992 | – | 160,992 |
| Net loss | – | – | – | (3,601,623) | (3,601,623) |
| Balances, January 31, 2026 | 99,853,763 | 99,854 | 56,135,234 | (66,830,907) | (10,595,819) |
| Common stock issued for conversion of accrued interest and fees | 419,900 | 420 | 29,812 | – | 30,231 |
| Common stock issued for conversion of outstanding principal, accrued interest and fees | 695,000 | 695 | 49,345 | – | 50,040 |
| Net income | – | – | – | 765,890 | 765,890 |
| Balances, April 30, 2026 | 100,968,663 | $100,969 | $56,214,391 | $(66,065,017) | $(9,749,657) |
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Dollars | Capital | Deficit | Deficit | |
| Balances, July 31, 2024 | 96,709,763 | $96,710 | $55,572,687 | $(61,003,146) | $(5,333,749) |
| Stock-based compensation | – | – | 60,487 | – | 60,487 |
| Warrants issued in debt financing | – | – | 13,343 | – | 13,343 |
| Net loss | – | – | – | (1,018,906) | (1,018,906) |
| Balances, October 31, 2024 | 96,709,763 | 96,710 | 55,646,517 | (62,022,052) | (6,278,825) |
| Stock-based compensation | – | – | 36,131 | – | 36,131 |
| Net loss | – | – | – | (220,126) | (220,126) |
| Balances, January 31, 2025 | 96,709,763 | 96,710 | 55,682,648 | (62,242,178) | (6,462,820) |
| Stock-based compensation | – | – | 11,781 | – | 11,781 |
| Net loss | – | – | – | (251,743) | (251,743) |
| Balances, April 30, 2025 | 96,709,763 | $96,710 | $55,694,429 | $(62,493,921) | $6,702,782 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.